

Prognosis of unrecognized myocardial infarction determined by electrocardiogram or cardiac magnetic resonance imaging: systematic review and meta-analysis

BMJ
BMJ-2019-053363
Research
ВМЈ
31-Oct-2019
Yan, Yu ; Affiliated Hospital of Guangdong Medical University, Zhanjiang, Geriatrics Li, Wensheng ; Shunde Hospital, Southern Medical University, Cardiology Zhu, Hailan ; Shunde Hospital, Southern Medical University, Cardiology Pan, Xiongfei ; Vanderbilt University Medical Center, Nashville, Medicine Hu, Yunzhao; The First People's Hospital of Shunde, Clinical Medicine Research Center Arnott, Clare ; George Institute for Global Health, Cardiology Mai, Weiyi ; First Affiliated Hospital of Sun Yat-sen University, Cardiology Cai, Xiaoyan; Shunde Hospital, Southern Medical University Huang, Yuli; George Institute for Global Health, Cardiology; Shunde Hospital, Southern Medical University, Cardiology
Unrecognized myocardial infarction, Electrocardiogram, Cardiac magnetic resonance, Prognosis, Major adverse cardiac outcomes, All-cause mortality

SCHOLARONE[™] Manuscripts

RESEARCH

Prognosis of unrecognized myocardial infarction determined by electrocardiogram or cardiac magnetic resonance imaging: systematic review and meta-analysis

Brief Title: Prognosis of unrecognized myocardial infarction

Yu Yan, *professor, MD,PhD*¹ Wensheng Li, *associate professor, MD*² Hailan Zhu, *resident doctor*² Xiongfei Pan, *statistician,PhD*³ Yunzhao Hu, *professor, MD,PhD*² Clare Arnott, *senior research fellow,PhD*⁴ Weiyi Mai, *professor, MD,PhD*⁵ Xiaoyan Cai, *associate professor, MD*⁶ Yuli Huang, *professor, MD,PhD*^{2,4}

¹Department of Geriatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China;

² Department of Cardiology, Shunde Hospital, Southern Medical University, Foshan, China;

³ Department of Medicine, Vanderbilt University Medical Center, Nashville,

Tennessee, USA;

⁴Department of Cardiology, The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia;

⁵ Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University,

BMJ

Guangzhou, China;

⁶ Department of Scientific Research and Education, Shunde Hospital, Southern Medical University, Foshan, China

Correspondence To:

Dr Yuli Huang, MD, PhD, Department of Cardiology, Shunde Hospital, Southern Medical University, Jiazhi Road, Lunjiao Town, Shunde District, Foshan, 528300, PR China; The George Institute for Global Health, Faculty of Medicine, University of , (hyuli82), New South Wales, Sydney, Australia (hyuli821@smu.edu.cn;

yhuang@georgeinstitute.org.au).

Word count: 3612 words

 BMJ

Abstract

Objectives Unrecognized myocardial infarction (UMI) is highly prevalent, however, whether screening UMI can improve cardiovascular outcomes remains controversial. We evaluated the prognosis of UMI determined by electrocardiogram (UMI-ECG) or cardiac magnetic resonance imaging (UMI-CMR).

Design Meta-analysis of prospective studies.

Data sources Electronic databases (PubMed, EMBASE and Google Scholar). **Study selection** Prospective cohort studies were included for meta-analysis if they reported adjusted relative risks (RRs) for all-cause mortality or cardiovascular outcomes of UMI compared with non-myocardial infarction (MI).

Data extraction and synthesis Data were extracted independently by two investigators. Random-effects models were used to calculate the RRs and 95% confidence intervals (CIs). The primary outcomes were composite major adverse cardiac outcomes (MACEs), all-cause and cardiovascular mortality associated with UMI as defined by ECG and CMR respectively. The secondary outcomes were the risks of recurrent coronary heart disease (CHD)/MI, stroke, heart failure, and atrial fibrillation. The ratio of RRs for outcomes between clinically recognized MI (RMI) and UMI were calculated.

Results Thirty-one studies comprising 253,425 participants with 1,621,920 participant-years of follow-up were included. Compared with non-MI, UMI detected by ECG was associated with increased risks of all-cause mortality (RR 1.51, 95% CI 1.30 to 1.76), cardiovascular mortality (RR 2.33, 95% CI 1.66 to 3.27) and MACEs

(RR 1.61, 95% CI 1.38 to 1.89). UMI detected by CMR was also associated with increased risks of all-cause mortality (RR 2.16, 95% CI 1.39 to 3.35), cardiovascular mortality (RR 10.79, 95% CI 4.09 to 28.42), and MACEs (RR 3.23, 95% CI 2.10 to 4.95). Compared with UMI detected by ECG, RMI was only associated with increased risks of recurrent CHD/MI (ratio of RR 2.22, 95% CI 1.33 to 3.71) and heart failure (ratio of RR 1.84, 95% CI 1.42 to 2.38); but without difference with all other outcomes. Additionally, no significant difference was observed for any outcomes between RMI and UMI detected by CMR.

BMJ

Conclusions UMI, detected by either ECG or CMR, is associated with an adverse long-term prognosis similar to that of RMI. Screening for UMI is useful for risk stratification in the management of patients with a high risk of cardiovascular disease.

Key Words: Unrecognized myocardial infarction, electrocardiogram, cardiac magnetic resonance imaging, prognosis, cardiac outcomes

BMJ

What is already known on this topic

Unrecognized myocardial infarction (UMI) is highly prevalent, especially in patients with diabetes and those of older age.

It also remains unclear whether identification of UMI offers any additional prognostic value over important traditional cardiovascular risk factors.

Contemporary academic guidelines for cardiovascular disease prevention have raised great concerns about the significance of screening for myocardial ischaemia in asymptomatic individuals.

What this study adds

UMI was associated with increased risks of all-cause mortality and multiple adverse cardiovascular outcomes compared with the absence of myocardial infarction. Electrocardiogram and cardiac magnetic resonance can provide different information, and each modality has unique clinical value in the detection of UMI. Screening for UMI is useful for risk stratification in the management of patients with a high risk of cardiovascular disease.

Introduction

Unrecognized myocardial infarction (UMI) is defined as myocardial infarction (MI) that was not detected during the acute phase due to lack of or atypical symptoms, but later discovered by finding of pathological Q waves on electrocardiogram (ECG), myocardial imaging evidence, or pathological findings on autopsy.¹² Prior studies have shown that UMI accounts for one-third to one-half of all MIs,¹⁻⁴ especially in patients with diabetes and those of older age.⁵⁶

Some epidemiological studies have shown that UMI detected by ECG (UMI-ECG) is associated with subsequent increased risks of all-cause mortality, recurrent cardiovascular disease (CVD), and heart failure,⁷⁻⁹ although other studies found null associations.¹⁰⁻¹² Furthermore, it also remains unclear whether identification of UMI-ECG offers any additional prognostic value over important conventional cardiovascular risk factors,¹⁰¹¹ Therefore, contemporary academic guidelines for CVD prevention have raised great concerns about the significance of screening for myocardial ischaemia in asymptomatic individuals using ECG, even in those with a high risk of CVD.^{13 14} In recent years, late gadolinium enhancement cardiac magnetic resonance imaging (CMR) has also been employed to detect UMI,¹ ¹⁵ However, the diagnostic consistency between ECG and CMR has not been thoroughly explored. The high cost and time-consuming nature of CMR has so far also limited its clinical application and use in large cohort studies, although a handful of studies have shown that UMI detected by CMR (UMI-CMR) is associated with an increased mortality risk.1116

Due to these inconsistencies, we performed a systematic review and

meta-analysis of prospective cohort studies to synthesize available data on the prognostic value of UMI-ECG and UMI-CMR. Three key questions were explored in our study: 1) Is UMI-ECG or UMI-CMR associated with a poorer prognosis in terms of CVD and mortality than the absence of MI? 2) Is the prognosis of UMI different from that of clinically recognized MI (RMI)? 3) What is the value of screening UMI with ECG or CMR?

Methods

Search strategy and selection criteria

Following the recommendations of the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group,¹⁷ several electronic databases (PubMed, EMBASE, and Google Scholar) were searched for prospective studies up to 30 June 2019. The search was restricted to human studies, but no restrictions were placed on language or publication form. Reference lists were manually checked to identify other potential studies. The detailed method that was used to search PubMed is presented in eTable 1 in Online Supplementary File 1.

Studies were included in the analysis if they met the following criteria: (1) prospective cohort studies with adult participants (age of \geq 18 years), (2) UMI and other cardiovascular risk factors were detected at baseline, and (3) adjusted hazard ratios (HRs) or relative risks (RRs) and 95% confidence intervals (CIs) reported for all-cause death or cardiovascular outcomes (including cardiovascular mortality, composite major adverse cardiac outcomes [MACEs], new coronary heart disease

[CHD]/MI, stroke, heart failure, and atrial fibrillation) associated with UMI versus those without MI. UMI was defined as signs of MI shown by ECG or CMR without a documented history of acute MI. RMI was defined as a documented clinical history of MI. Non-MI was defined as not having RMI or ECG-/CMR-positive findings of MI.

BMJ

Studies were excluded if (1) the diagnosis of UMI was not based on ECG or CMR, (2) only unadjusted risks were reported for associated events, and (3) identical outcomes were derived from the same cohort. For multiple articles reporting identical outcomes from the same cohort, only the most recently published paper was included 0.5 in the analysis.

Patient involvement

Patients were not involved in setting the research question, in the outcome measures, in the design, or in the implementation of the study. No patients were asked to advice on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Data extraction and quality assessment

Two reviewers (J.W. and W.L.) independently conducted the literature searches and screened the studies according to the pre-defined criteria. The following study data were recorded: participant characteristics, ethnicity, study sample, methods and criteria for detecting UMI, age, sex, adjusted risk factors, follow-up duration, and outcomes assessment.

BMJ

Quality assessment of the included studies was based on the Newcastle-Ottawa Quality Assessment Scale for cohort studies,¹⁸ in which a study is judged based on selection (four items, one point each), comparability (one item, up to two points), and exposure/outcome (three items, one point each). In the present analysis, the quality of all included studies was graded as good (≥ 7 points), fair (4–6 points), or poor (<4 points).

We also evaluated whether the studies had been adequately adjusted for potential confounders (at least six of the following seven factors: sex, age, smoking, hypertension or blood pressure or antihypertensive treatment, diabetes mellitus or fasting plasma glucose or hemoglobin A_{1c}, body mass index or overweight/obesity, and serum cholesterol or hypercholesterolemia) or whether they had been adjusted for risk scores for prediction of CVD, calculated from these metrics, with reference to previous studies.¹⁹⁻²¹ rej.

Statistical analysis

The primary outcomes were the risks of MACEs, all-cause and cardiovascular mortality associated with UMI-ECG and UMI-CMR, compared with non-MI. The secondary outcomes were the risks of recurrent CHD/MI, stroke, heart failure, and atrial fibrillation. To explore whether the prognosis of UMI differs from that of clinical RMI, the aforementioned outcomes for RMI compared with non-MI were also extracted. The ratio of RRs for outcomes between RMI and UMI were calculated according to published methods.²²

Outcomes adjusted for multiple variables were extracted for the meta-analysis. If a study reported multiple results based on different numbers of covariates included in statistical adjustments, the result that adjusted for the most number of variables were extracted for the meta-analysis. We combined the log RRs and corresponding standard errors (SEs) by the inverse variance approach. If outcomes were presented as odds ratios (ORs), data were converted to RRs by the formula (RR = OR / ([1 - pRef])+ $[pRef \times OR]$) for analysis, where pRef is the prevalence of the outcome in the reference group.¹⁹ We used I² statistics to test heterogeneity. An I² value of >50% was considered to indicate significant heterogeneity. However, even when no statistically significant heterogeneity was found, we used the DerSimonian and Laird random-effects models as the primary approach to pool results across studies rather than the fixed-effects model, due to underlying clinical and methodological heterogeneity (e.g., baseline characteristics of the patients, adjustment for confounders, and follow-up duration). Subgroup analyses of the primary outcomes were conducted according to sex (men vs. women), ethnicity (Asian vs. non-Asian), age (average of <65 vs. ≥ 65 years), enrolment from a community-based population (ves vs. no), presence of diabetes (ves vs. no), follow-up duration (<6 vs. \geq 6 years), adjustment for confounders (adequate vs. inadequate), and study quality (good vs. fair) if appropriate. Publication bias was evaluated by inspecting funnel plots for primary outcomes and further tested using Begg's test and Egger's test. To assess the impact of individual studies on the estimated risk, a sensitivity analysis was conducted in which the pooled RR was recalculated by omitting one study at a time.

BMJ

BMJ

To assess whether screening with ECG or CMR can add additional predictive value on top of traditional cardiovascular risk factors, we reviewed studies with data regarding improvement of risk prediction (e.g., change with area under the receiver operating characteristic curve, integrated discrimination improvement [IDI], or net reclassification improvement). We also summarized the diagnostic consistency of UMI-ECG and UMI-CMR from studies that used both ECG and CMR to detect UMI.

Analyses were performed using Stata 12.0 (StataCorp LP, College Station, TX, USA) and RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). All *P* values are two-tailed, and statistical significance was set at 0.05.

Results

Studies retrieved and characteristics

Our initial search returned 17,687 articles. After screening the titles and abstracts, 116 articles qualified for a full text review (Figure 1). Finally, 30 published papers involving 253,425 participants were included in the analysis.^{7 10-12 16 23-47} According to the Newcastle–Ottawa quality assessment, only two studies were graded as having fair quality; all other studies were graded as having good quality. The details of the quality assessment are presented Online Supplementary File 2.

UMI-ECG and health outcomes

Twenty studies reported outcomes data associated UMI-ECG.^{7 10-12 23-38} The key characteristics of the included studies are presented in Online Supplementary File 3.

The studies comprised 250,407 participants with a mean follow-up duration of 6.4 years (range, 2.3–17 years). Fifteen studies were derived from the general population, two studies included patients with chronic kidney disease, two studies included patients with diabetes, and one study included patients with stable coronary artery disease. Seven studies were not adequately adjusted for potential confounders, while all others were adequately adjusted (Online Supplementary File 4). The prevalence of UMI-ECG in the cohorts ranged from 0.3% to 16.6% and constituted 22.9%-61.7% for all MIs.

BMJ

Random-effects model analyses showed that compared with non-MI, UMI-ECG was associated with increased risks of all-cause mortality (RR: 1.51, 95% CI: 1.30 to 1.76), cardiovascular mortality (RR: 2.33, 95% CI: 1.66 to 3.27), and MACEs (RR: 1.61, 95% CI: 1.38 to 1.89) (Figure 2). Furthermore, UMI-ECG was also associated with increased risks of new CHD/MI (RR: 1.66, 95% CI: 1.25 to 2.20) and heart failure (RR: 1.50, 95% CI: 1.22 to 1.85), but not stroke (RR: 1.55, 95% CI: 0.75 to 3.19) or atrial fibrillation (RR: 1.44, 95% CI: 0.61 to 3.39) (Figure 3). No publication bias was detected based on inspection of the funnel plot (Online Supplementary File 5) or Begg's test and Egger's test (both P > 0.05).

UMI-CMR and health outcomes

Ten studies including 3,018 participants reported the prognostic outcomes of UMI-CMR.^{16 39-47} The key characteristics of the included studies are summarized in Online Supplementary File 6. The mean follow-up duration was 6.4 years (range, 1.3–

Page 13 of 57

BMJ

11 years). Two studies were derived from the general population, two studies included patients with acute MI, three studies included patients with diabetes/impaired fasting glucose, and three studies included patients with stable coronary artery disease. Three studies were not adequately adjusted for potential confounders,^{40 41 45} while all others were adequately adjusted (Online Supplementary File 4). The prevalence of UMI-CMR in the cohorts ranged from 8.2% to 31.0% and constituted 51% to 83.3% for all MIs.

Random-effects model analyses showed that compared with non-MI, UMI-CMR was associated with increased risks of all-cause mortality (RR: 2.16, 95% CI: 1.39 to 3.35]), cardiovascular mortality (RR: 10.79, 95% CI: 4.09–28.42), and MACEs (RR: 3.23, 95% CI: 2.10 to 4.95). Each 1% and 10% increase in late gadolinium enhancement was associated with a 9% and 77% increase in MACEs, respectively (Figure 4). One study showed that compared with the non-MI, UMI-CMR was associated with increased risks of future MI (RR: 1.87, 95% CI: 1.28 to 2.73) and heart failure (RR: 1.40, 95% CI: 1.00 to 2.00) after adjusting for multiple risk factors ³⁹. Possible publication bias could not be excluded as detected by the funnel plot for the MACEs (Online Supplementary File 7) and as also shown by Begg's test (P = 0.01) and Egger's test (P = 0.03). However, applying the trim-and-fill adjustment method produced no change in the overall effect estimate for MACEs associated with UMI-CMR.

Comparison of prognosis between UMI and clinical RMI

When cardiovascular outcomes or mortality associated with UMI and clinical RMI were reported in the same study, data were pooled to explore whether the prognosis differed between UMI and RMI. Compared with the non-MI, no significant heterogeneity was observed between UMI-ECG and RMI for the risks of all-cause mortality, cardiovascular mortality, MACEs, or stroke, although the risks of recurrent CHD/MI and heart failure were higher in RMI (Figure 5a). No significant heterogeneity was observed for health outcomes between RMI and UMI-CMR when compared with the non-MI (Figure 5b). The ratio of RRs for outcomes also showed that when compared with UMI-ECG, RMI was only associated with increased risks of recurrent CHD/MI (ratio of RRs: 2.22, 95% CI: 1.33 to 3.71) and heart failure (ratio of RRs: 1.84, 95% CI: 1.42 to 2.38), but without a difference with any of the primary outcomes. No significant difference for the ratio of RRs was observed for all outcomes between RMI and UMI-CMR (Online Supplementary File 8).

BMJ

Subgroup analyses and sensitivity analyses

The pre-defined subgroup analyses showed that compared with non-MI, UMI-ECG was associated with increased risks of all-cause mortality and cardiovascular mortality among all subgroup comparisons (Online Supplementary File 9). CMR-UMI was associated with increased risks of all primary outcomes among all subgroup comparisons (Online Supplementary File 10). We did not perform subgroup analyses for the other cardiac outcomes because of the limited number of studies available.

erie

The sensitivity analyses confirmed that the association between primary endpoint

BMJ

events and UMI-ECG or UMI-CMR did not change with the use of random-effects models or fixed-effects models for the meta-analysis or with recalculation of the RRs by omitting one study at a time.

Additional predictive effects for health outcomes of UMI

Few studies reported the additional predictive effects of ECG-UMI.^{11 16 30} The United Kingdom Prospective Diabetes Study showed that in patients with type 2 diabetes, UMI-ECG was associated with small but statistically significant improvement in all-cause mortality (IDI, 0.0025 [0.001–0.0039]) and fatal MI risk stratification (IDI, 0.0025 [0.001–0.0039]) in the model adjusted for age, sex, ethnicity, smoking, glycated haemoglobin, systolic blood pressure, and ratio of total cholesterol to high-density lipoprotein cholesterol.³⁰ However, other studies showed that the addition of UMI-ECG did not improve the risk prediction for future recurrent MI or mortality using the Framingham Risk Score.^{10 11} Three studies consistently showed that UMI-CMR can improve the risk prediction for all-cause mortality or MACEs (Table 1).

Diagnostic consistency between ECG and CMR

Five studies reported diagnostic consistency between ECG and CMR for UMI detection.^{11 16 41 45 47} Pooled data from 1731 participants showed that when CMR was used as gold standard, ECG for diagnosing UMI was with low sensitivity (13.2%) and positive predictive value (40.8%), while with high specificity (95.7%) and negative

predictive value (83.1%) (Table 2). McNemar's test showed a statistically significant difference between ECG and CMR for UMI detection (6.0% vs. 18.3%, respectively; P < 0.001).

BMJ

Discussion

Principal findings

To our knowledge, this is the first comprehensive systematic review and meta-analysis to examine the mortality and cardiovascular outcomes associated with UMI, stratified by detection with ECG or CMR. Three key findings in our study are as follows. 1) Compared with the absence of MI, UMI-ECG and UMI-CMR were associated with increased risks of all-cause mortality and multiple cardiovascular outcomes. 2) Compared with clinical RMI, ECG-UMI and CMR-UMI were associated with similar risks of all-cause mortality and MACEs. 3) ECG screening for UMI has low sensitivity but high specificity, which may add additional predictive effects for mortality and new MI; however, the results are inconsistent. In contrast, screening with CMR can significantly increase the predictive effects for mortality and CVD.

Meaning of the study and Future research

Our results provide robust evidence that although asymptomatic, UMI is associated with a poorer long-term prognosis compared with non-MI, and similarly to clinical RMI. Depending on the different characteristics of the included studies, the prevalence of UMI-ECG was 22.9%-61.7%, and UMI-CMR was up to 51%-83.3% in

Page 17 of 57

BMJ

all MIs. Considering the highly prevalence and significant adverse long-term prognosis associated with UMI, it is with important clinical impacts to screen and proper manage these patients.

Who should be screened for UMI

The use of ECG to screen asymptomatic adults for CVD is controversial. The United States Preventive Services Task Force suggests that the current evidence is insufficient to assess the balance of benefits and harms of screening with ECG in adults with an intermediate or high risk of CVD events.¹³ However, the American College of Cardiology/American Heart Association (ACC/AHA) guideline considers ECG screening to be 'reasonable' in asymptomatic people with hypertension or diabetes and that it 'may be considered' in those without hypertension or diabetes.⁴⁸ The 2019 European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases stated that 'resting ECG is recommended in patients with diabetes mellitus with hypertension or suspected CVD.⁴⁹ However, both the ACC/AHA and ESC guidelines acknowledged the lack of data to support this expert consensus (level of evidence: C). Therefore, the robust evidence in the current study, which showed that UMI-ECG was associated with adverse outcomes, is supportive for developing strategies for screening and preventing CVD. However, limited data showed that ECG can add additional predictive effects for mortality and new MI, and the results were inconsistent. These inconsistencies may arise from the fact that most of the studies included patients with a low risk of CVD. In this context, further studies are needed to evaluate the impact of ECG on incremental

BMJ

> improvements in risk stratification in high-risk patients. A large-scale registry study from Spain showed that although the positive predictive value of asymptomatic Q waves for diagnosing UMI was 29.2% overall, it was much higher (75%) in participants with a 10-year CHD risk of \geq 10% than in lower-risk participants.³ Therefore, we agree with the Canadian diabetes guideline that screening ECG should be performed in patients with a high risk of CVD. This screening can not only provide information on baseline cardiac ischemia but can also provide information for comparison with future ECG data⁵⁰⁵⁰⁵⁰. A repeat resting ECG may detect changes that result from UMI, leading to earlier detection of critical CVD.

How to screen for UMI

Although ECG is the most widely used non-invasive technique for cardiovascular assessment, it had been questioned for its limited sensitivity for screening UMI. It is known that Q waves can resolve with time, and patients with non-ST segment elevation MI do not have characteristic Q waves on ECG.⁵¹ Our study also showed that the use of ECG to detect UMI has a low sensitivity (13.2%) and positive predictive value (40.8%) but that it has a high specificity (95.7%) and negative predictive value (83.1%). Therefore, it is important to develop more precise, sophisticated ECG-based models for estimating UMI. This is possible given the availability of digital ECG data, which provide hundreds of waveform measurements and development of machine learning technology.⁵²

Not surprisingly, CMR can detect more cases of UMI than ECG. However, the high cost and time-consuming nature of CMR limit its application in daily clinical

BMJ

practice. Furthermore, the intravenous gadolinium used in CMR may pose a risk of nephrogenic systemic fibrosis in patients with kidney disease.⁵³ Therefore, we should note that ECG and CMR can provide different information, and each modality has unique clinical value in the detection of UMI. Further studies are needed to explore how to integrate ECG and CMR rather than replace one with the other to screen and manage patients with a risk of myocardial ischemia. We also propose that if UMI is identified by ECG during routine clinical care, CMR could be performed to identify the presence and extent of actual myocardial damage and guide treatment decisions.⁵⁴

How to manage patients with UMI

Two randomized trials showed that compared with simple control of cardiovascular risk factors, screening for silent ischemia with a stress test does not improve the prognosis in patients with diabetes.⁵⁴ Although these studies had limited samples and were under-powered, they emphasized the importance of controlling cardiovascular risk factors in the treatment of asymptomatic coronary artery disease. In real clinical practice, however, many patients with UMI are undertreated. In the REasons for Geographic And Racial Differences in Stroke (REGARDS) study, only 44.4%, 25.8%, and 33.9% of patients with UMI received treatment of aspirin, β-blockers, and statins, respectively; these rates were significantly lower than those of patients with clinical RMI.⁵⁷ Similar results were observed in the ICELAND MI study and were attributed to the high mortality of patients with UMI.¹¹ Therefore, further efforts should be made to increase the adherence to guideline recommendations for prevention of CVD in patients with UMI. In selected patients, adjunctive coronary

revascularization is worthy of prospective testing. A recently cohort study of 9,897 patients with silent ischemia showed that compared with medical treatment, coronary revascularization was associated with a 19% and 42% reduction of death and MI, respectively, during a median follow-up duration of 4.6 years.⁵⁸

BMJ

Strengths and limitations of study

 Our study has several major strengths. First, we included and stratified studies of ECG or CMR, which are the most prevalent methods for screening UMI. Second, only prospective cohort studies with adjusted RRs were included. Most of the included studies were of high quality and adequately adjusted for confounders. Third, the sample size was large and the follow-up duration was long (more than 1.6 million person-years).

However, some limitations of the study should be noted. First, we had no access to individual participants' data. However, only studies with multivariate-adjusted data were included in the analysis, and consistent results were found in the comprehensive subgroup analyses and sensitivity analyses. These characteristics may mitigate the possibility of influencing the association between UMI and outcomes by confounding factors. Second, most studies using CMR screening involved patients with special conditions such as diabetes or chronic kidney disease. These patients had higher risks than those included in ECG screening; thus, direct comparison of CVD risks between UMI-ECG and UMI-CMR was unavailable. Third, UMI-ECG was defined with different criteria in included studies, which was an underlying factor for the heterogeneity among the studies.

 BMJ

Conclusions

Our study has shown that UMI is highly prevalent and associated with an adverse long-term prognosis, which is similar to that of clinical RMI. Screening for UMI is useful for risk stratification in the management of patients with a high risk of CVD. Further studies are needed to develop standard methods for screening and treating UMI.

Funding: The project was supported by the National Natural Science Foundation of China (No: 81600239), the Science and Technology Innovation Project from Foshan, Guangdong (FS0AA-KJ218-1301-0006) and the Clinical Research Startup Program of Shunde Hospital, Southern Medical University (CRSP2019001).

Contributors: Y.Y, X.C and Yul.H were responsible for the initial plan, study design, conducting the study, data interpretation. Y.Y, W.L, H.Z, W.M, X.C and Yul.H was responsible for data collection, data extraction, statistical analysis and manuscript drafting. Y.Y, W.L, X.P, Yun.H, C.A and Yul.H were responsible for analyzed and interpreted the data and critically revised the paper. X.C and Yul.H are guarantors and had full access to all of the data, including statistical reports and tables), and take full responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests: All author shave completed the ICMJE uniform disclosure form at <u>www.icmje.org/coi_disclosure.pdf (available on</u> request from the corresponding author) and declare: no support from any organization for the

<text><text><text><text> submitted work; no financial relationships with any organizations that might have an

BMJ

 BMJ

References

1. Turkbey EB, Nacif MS, Guo M, et al. Prevalence and Correlates of Myocardial Scar in a US Cohort. *JAMA* 2015;314:1945-54.

2. de Torbal A, Boersma E, Kors JA, et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. *Eur Heart J* 2006;27:729-36.

3. Ramos R, Albert X, Sala J, et al. Prevalence and incidence of Q-wave unrecognized myocardial infarction in general population: Diagnostic value of the electrocardiogram. The REGICOR study. *Int J Cardiol* 2016;225:300-305.

4. Barbier CE, Nylander R, Themudo R, et al. Prevalence of unrecognized myocardial infarction detected with magnetic resonance imaging and its relationship to cerebral ischemic lesions in both sexes. *J Am Coll Cardiol* 2011;58:1372-7.

5. Stacey RB, Zgibor J, Leaverton PE, et al. Abnormal Fasting Glucose Increases Risk of Unrecognized Myocardial Infarctions in an Elderly Cohort. *J Am Geriatr Soc* 2019;67:43-49.

6. Soejima H, Ogawa H, Morimoto T, et al. One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. *J Cardiol* 2019;73:33-37.

7. Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middle-aged men. *Eur Heart J* 2000;21:1052-62.

8. Sheifer SE, Gersh BJ, Yanez NR, Ades PA, Burke GL, Manolio TA. Prevalence,

predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. *J Am Coll Cardiol* 2000;35:119-26.

9. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. *Ann Intern Med* 1995;122:96-102.

10. Ohrn AM, Schirmer H, Njolstad I, et al. Electrocardiographic unrecognized myocardial infarction does not improve prediction of cardiovascular events beyond traditional risk factors. The Tromso Study. *Eur J Prev Cardiol* 2018;25:78-86.

11. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. *JAMA* 2012;308:890-6.

12. Jovanova O, Luik AI, Leening MJ, et al. The long-term risk of recognized and unrecognized myocardial infarction for depression in older men. *Psychol Med* 2016;46:1951-60.

13. Curry SJ, Krist AH, Owens DK, et al. Screening for Cardiovascular Disease RiskWith Electrocardiography: US Preventive Services Task Force RecommendationStatement. *JAMA* 2018;319:2308-2314.

14. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018;41S86-S104.

15. Merkler AE, Sigurdsson S, Eiriksdottir G, et al. Association Between Unrecognized Myocardial Infarction and Cerebral Infarction on Magnetic Resonance Imaging. *JAMA Neurol* 2019. doi: 10.1001/jamaneurol.2019.1226.

BMJ

16. Elliott MD, Heitner JF, Kim H, et al. Prevalence and Prognosis of UnrecognizedMyocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center StudyWith Up to 5 Years of Follow-up. *Diabetes Care* 2019;42:1290-6.

17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283:2008-12.

18. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical epidemiology/oxford.asp.

19. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. *BMJ* 2016;355:i5953.

20. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med* 2001;20:21-35.

21. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. *J Hypertens* 2017;35:677-688.

22. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219.

23. Ahmad MI, Dutta A, Anees MA, Soliman EZ. Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population. *Am J Cardiol* 2019;123:882-888.

24. Qureshi WT, Zhang ZM, Chang PP, et al. Silent Myocardial Infarction and

Long-Term Risk of Heart Failure: The ARIC Study. J Am Coll Cardiol 2018;71:1-8.

 BMJ

25. Farag AA, AlJaroudi W, Neill J, et al. Prognostic value of silent myocardial infarction in patients with chronic kidney disease being evaluated for kidney transplantation. *Int J Cardiol* 2017;249:377-382.

26. van der Ende MY, Hartman M, Schurer R, et al. Prevalence of electrocardiographic unrecognized myocardial infarction and its association with mortality. *Int J Cardiol* 2017;243:34-39.

27. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2016;133:2141-8.

28. Hadaegh F, Ehteshami-Afshar S, Hajebrahimi MA, Hajsheikholeslami F, Azizi F. Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up. *Int J Cardiol* 2015;182:334-9.

29. Dehghan A, Leening MJ, Solouki AM, et al. Comparison of prognosis in unrecognized versus recognized myocardial infarction in men versus women >55 years of age (from the Rotterdam Study). *Am J Cardiol* 2014;113:1-6.

30. Davis TM, Coleman RL, Holman RR. Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. *Circulation* 2013;127:980-7.

31. Krijthe BP, Leening MJ, Heeringa J, et al. Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. *Int J Cardiol* 2013;168:1453-7.

BMJ

32. Rizk DV, Gutierrez O, Levitan EB, et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. *Nephrol Dial Transplant* 2012;27:3482-8.

33. Kehl DW, Farzaneh-Far R, Na B, Whooley MA. Prognostic value of electrocardiographic detection of unrecognized myocardial infarction in persons with stable coronary artery disease: data from the Heart and Soul Study. *Clin Res Cardiol* 2011;100:359-66.

34. Leening MJ, Elias-Smale SE, Felix JF, et al. Unrecognised myocardial infarction and long-term risk of heart failure in the elderly: the Rotterdam Study. *Heart* 2010;96:1458-62.

35. Ammar KA, Makwana R, Jacobsen SJ, et al. Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography. *Ann Noninvasive Electrocardiol* 2007;12:27-37.

36. Ikram MA, Hollander M, Bos MJ, et al. Unrecognized myocardial infarction and the risk of stroke: the Rotterdam Study. *Neurology* 2006;67:1635-9.

37. Davis T, Fortun P, Mulder J, Davis WA, Bruce DG. Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. *Diabetologia* 2004;47:395-399.

38. Menotti A, Mulder I, Kromhout D, Nissinen A, Feskens EJ, Giampaoli S. The association of silent electrocardiographic findings with coronary deaths among elderly men in three European countries. The FINE study. *Acta Cardiol* 2001;56:27-36.

BMJ

 39. Acharya T, Aspelund T, Jonasson TF, et al. Association of Unrecognized Myocardial Infarction With Long-term Outcomes in Community-Dwelling Older Adults: The ICELAND MI Study. *JAMA Cardiol* 2018;3:1101-1106.

40. Nordenskjold AM, Hammar P, Ahlstrom H, Bjerner T, Duvernoy O, Lindahl B. Unrecognized myocardial infarction assessed by cardiac magnetic resonance imaging is associated with adverse long-term prognosis. *PLoS One* 2018;13:e0200381.

41. Amier RP, Smulders MW, van der Flier WM, et al. Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. *JACC Cardiovasc Imaging* 2018;11:1773-1781.

42. Omori T, Kurita T, Dohi K, et al. Prognostic impact of unrecognized myocardial scar in the non-culprit territories by cardiac magnetic resonance imaging in patients with acute myocardial infarction. *Eur Heart J Cardiovasc Imaging* 2018;19:108-116.

43. Barbier CE, Themudo R, Bjerner T, Johansson L, Lind L, Ahlstrom H. Long-term prognosis of unrecognized myocardial infarction detected with cardiovascular magnetic resonance in an elderly population. *J Cardiovasc Magn Reson* 2016;18:43.

44. Yoon YE, Kitagawa K, Kato S, et al. Prognostic significance of unrecognized myocardial infarction detected with MR imaging in patients with impaired fasting glucose compared with those with diabetes. *Radiology* 2012;262:807-15.

45. Kim HW, Klem I, Shah DJ, et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. *PLoS Med* 2009;6:e1000057.

46. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of

BMJ

unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. *Circulation* 2008;118:1011-20.

47. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. *Circulation* 2006;113:2733-43.

48. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2010;122:e584-636.

49. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2019;40:3215-3217.

50. Poirier P, Dufour R, Carpentier A, Larose E. Screening for the presence of coronary artery disease. *Can J Diabetes* 2013;37 Suppl 1:S105-9.

51. Valensi P, Meune C. Congestive heart failure caused by silent ischemia and silent myocardial infarction : Diagnostic challenge in type 2 diabetes. *Herz* 2019;44:210-217.

52. Soliman EZ. Electrocardiographic definition of silent myocardial infarction in population studies: A call to standardize the standards. *J Electrocardiol* 2019;55:128-132.

BMJ

53. McWilliams RG, Frabizzio JV, De Backer AI, et al. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. *J Magn Reson Imaging* 2019. doi: 10.1002/jmri.26851.

54. Scirica BM. Prevalence, incidence, and implications of silent myocardial infarctions in patients with diabetes mellitus. *Circulation* 2013;127:965-7.

55. Lievre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. *Trials* 2011;12:23.

56. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301:1547-55.

57. Levitan EB, Gamboa C, Safford MM, et al. Cardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. *Vasc Health Risk Manag* 2013;9:47-55.

58. Czarnecki A, Qiu F, Elbaz-Greener G, et al. Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease. *JACC Cardiovasc Interv* 2019;12:232-241.

Figure Legends

Figure 1. Flow of papers through review.

CIs=confidence intervals; CMR=cardiac magnetic resonance; ECG=electrocardiogram;

RRs=relative risks; UMI=unrecognized myocardial infarction.

Figure 2. Forest plot of estimates for risks of primary outcomes associated with UMI-ECG. CIs=confidence intervals; UMI-ECG=unrecognized myocardial infarction detected by electrocardiogram; MACEs= major adverse cardiac outcomes.

Figure 3. Forest plot of estimates for risks of secondary outcomes associated with UMI-ECG. CIs=confidence intervals; UMI-ECG=unrecognized myocardial infarction detected by electrocardiogram.

Figure 4. Forest plot of estimates for risks of primary outcomes associated with UMI-CMR. CIs=confidence intervals; UMI-CMR=unrecognized myocardial infarction detected by cardiac magnetic resonance imaging; LGE=late gadolinium enhancement

Figure 5. Heterogeneity of all-cause mortality and cardiac outcomes between UMI and RMI, compared with no MI. (A) UMI detected by ECG; (B) UMI detected by CMR CMR=cardiac magnetic resonance; MACEs=major adverse cardiovascular events; MI=myocardial infarction; UMI=unrecognized myocardial infarction; RMI=clinical recognized myocardial infarction

Table 1. Risk classification comparing models with and without UMI for

BMJ

mortality and cardiovascular outcomes

Study and endpoint	and endpoint ROC AUC NRI (95%CI)		IDI (95%CI)	
ECG-UMI				
Schelbert 2012 (All-cause mo	rtality)			
Base Model*	-	Reference	Reference	
Baseline model+UMI	-	-0.05 (-0.17-0.05)	0.000 (-0.004-0.001)	
P value	-	0.35	0.71	
Davis 2013 (All-cause mortal	ity)			
Base Model [#]	0.699	-	Reference	
Baseline model+UMI	0.701	-	0.0025 [0.001-0.0039]	
P value	0.07	-	0.001	
Davis 2013 (Fatal MI)				
Base Model*	0.713	-	Reference	
Baseline model+UMI	0.718	-	0.0043 [0.0016-0.007]	
P value	0.16	-	0.002	
Ohrn 2018 (Future MI)				
Base Model [†]	0.681	-	-	
Baseline model+UMI	0.682		-	
P value	0.96		-	
CMR-UMI				
Schelbert 2012 (All-cause mo	rtality)			
Base Model*	-	Reference	Reference	
Baseline model+UMI	-	0.16 (0.01-0.31)	0.008 (0.004-0.013)	
P value	-	0.04	0.001	
Barbier 2016 (MACEs)				
Base Model [‡]	0.68	Reference	Reference	
Baseline model+UMI	0.75	0.67 (0.28-1.06)	0.068 (0.025-0.111)	
P value	0.04	0.0007	0.002	
Elliott 2019 (MACEs)				
Base Model [‡]	-	-	Reference	
Baseline model+UMI	-	-	0.156 (0.063-0.249)	
P value	-	-	0.001	

*Adjusted for age, sex, diabetes, and recognized MI.

#Adjusted for age, sex, ethnicity, smoking, hemoglobin A1c, systolic blood pressure, total cholesterol/

high-density lipoprotein cholesterol ratio.

[†]Adjusted for age, sex, hypertension, diabetes, smoking, total cholesterol/ high-density lipoprotein

BMJ

cholesterol, cholesterol lowering medication and family history of premature MI.

[‡] Adjusted for Framingham risk score

CMR-UMI=unrecognized myocardial infarction defined by cardiac magnetic resonance;

<text><text><text> ECG-UMI=unrecognized myocardial infarction defined by electrocardiography; IDI=integrated

discrimination improvement; NRI= net reclassification improvement; ROC AUC= area under the


curves of receiver operating characteristic curve; UMI=unrecognized myocardial infarction

CMR negative

ECG positive	42	61		Positive	predictive
ECG negative	275	1353		value=40.8% Negative value=83.1%	predictive
	Sensitivity= 13.2%	Specif	icity=95.7%		
0					
ECG=Electrocard	liogram; CMR=cardiac	magnetic	resonance;	UMI=unrecognized	myocardi
infarction					

Table 2 Diagnostic Accuracy of UMI by ECG compared with CMR

CMR positive






Figure 1. Flow of papers through review.

CIs=confidence intervals; CMR=cardiac magnetic resonance; ECG=electrocardiogram; RRs=relative

risks; UMI=unrecognized myocardial infarction.

ו ר	
2 3	
5 4	
5 6	
7	
8	
9	
10	
11	
12	
13	
12 13 14 15 16 17	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
50 51	
51	
52 53	
53 54	
54 55	
55 56	
50 57	
57	
58	

60

1





Figure 2. Forest plot of estimates for risks of primary outcomes associated with UMI-ECG. CIs=confidence intervals; UMI-ECG=unrecognized myocardial infarction detected by electrocardiogram; MACEs= major adverse cardiac outcomes.

				Risk Ratio			Risk Ratio
	log[Risk Ratio]	SE	Weight	IV, Random, 95% Cl	Year	IV.	/, Random, 95% Cl
New CHD/MI Ohrn 2018	0.0004	0.2538	16.6%	1.25 [0.76, 2.06]	204.0		
Farag 2017		0.2558					
Hadaegh 2015		0.1389	26.2%	1.72 [1.31, 2.26]			
Davis 2013		0.1179	28.1%	1.26 [1.00, 1.59]			⊢ ∎−
Lampe 2000	0.9933		17.9%	2.70 [1.70, 4.29]			
Subtotal (95% CI)			100.0%	1.66 [1.25, 2.20]			•
Heterogeneity: Tau ² = 0			P = 0.03)	; I² = 63%			
Test for overall effect: Z	= 3.54 (P = 0.00	04)					
Stroke							
Ohrn 2018	-0.1054	0.3536	31.7%	0.90 [0.45, 1.80]	2018	-	
lkram 2006		0.2472		1.25 [0.77, 2.03]			
Lampe 2000	1.2528	0.3684		3.50 [1.70, 7.21]	2000		
Subtotal (95% CI)			100.0%	1.55 [0.75, 3.19]			
Heterogeneity: Tau ² = 0 Test for overall effect: Z			= 0.02);	1*= / 5%			
		,					
Heart failure							
Qureshi 2018	0.3001	0.143		1.35 [1.02, 1.79]			
Leening 2010	0.5128	0.1397		1.67 [1.27, 2.20]	2010		
Subtotal (95% CI) Heterogeneity: Tau ² = 0	00: Chi8 = 1.12	df = 1 /D	100.0%	1.50 [1.22, 1.85]			-
Test for overall effect: Z			- 0.28),	1 - 12 %			
Atrial fibrillation	0.700	0 4 0 4 0	54.000	0.04 14 54 0.000	0040		
Krijthe 2013 male Krijthe 2013 female	-0.0834	0.1943	51.0% 49.0%	2.21 [1.51, 3.23] 0.92 [0.59, 1.44]	2013		
Subtotal (95% CI)	-0.0634	0.2301	49.0% 100.0%	1.44 [0.61, 3.39]			
Heterogeneity: Tau ² = 0	34 [·] Chi ² = 8.47	df = 1 (P)					
Test for overall effect: Z			0.001,				

Figure 3. Forest plot of estimates for risks of secondary outcomes associated with UMI-ECG. CIs=confidence intervals; UMI-ECG=unrecognized myocardial infarction detected by electrocardiogram.



Churche an Curbon	la afDiala Datial			Risk Ratio	Maar	Risk Ratio
Study or Subgroup All cause mortality	log[Risk Ratio]	SE	vveight	IV, Random, 95% Cl	rear	IV, Random, 95% Cl
-	0.47	0 4 2 4 0	20.00	4 60 14 36 3 031	204.0	-
Acharya 2018		0.1219	36.6%	1.60 [1.26, 2.03]		
Amier 2018	1.3533		10.7%	3.87 [1.21, 12.38]		
Schelbert 2012		0.1795	32.5%	1.45 [1.02, 2.06]		
Kim 2009		0.7742	7.0%	11.40 [2.50, 51.99]		
Kwong 2008 Subtotal (95% Cl)	1.2179	0.5116	13.2% 100.0%	3.38 [1.24, 9.21] 2.16 [1.39, 3.35]	2008	•
Heterogeneity: Tau ² =	0.12: Chi ² = 10.7	9. df = 4 i				
Test for overall effect:		•	,			
Cardiovascular mort	ality					
Kim 2009	2	1.0551	21 0.96	17.40 [2.20, 137.61]	2009	
Kwona 2006		0.5594	78.1%	9.43 [3.15, 28.23]		│ ₽
Subtotal (95% CI)	2.2400	0.0004	100.0%	10.79 [4.09, 28.42]	2000	
Heterogeneity: Tau ² =	0.00; Chi ² = 0.26,	df = 1 (F	e = 0.61);			
Test for overall effect:						
MACEs						
Elliott 2019	2.0794	0.5004	8.9%	8.00 [3.00, 21.33]	2019	—•
Acharya 2018	0.3988	0.1147	15.8%	1.49 [1.19, 1.87]	2018	
Nordenskjold 2018	0.8329	0.3319	12.0%	2.30 [1.20, 4.41]	2018	
Amier 2018	1.1314	0.4758	9.3%	3.10 [1.22, 7.88]		
Omori 2018	1.1939	0.4448	9.8%	3.30 [1.38, 7.89]	2018	
Barbier 2016	0.9361	0.3846	11.0%	2.55 [1.20, 5.42]		
Yoon 2012	1.3762	0.364	11.4%	3.96 [1.94, 8.08]	2012	· · · · ·
Kwong 2008	1.3584	0.3603	11.4%	3.89 [1.92, 7.88]	2008	
Kwong 2006	1.7884	0.4095	10.5%	5.98 [2.68, 13.34]	2006	
Subtotal (95% CI)			100.0%	3.23 [2.10, 4.95]		•
Heterogeneity: Tau ² =		•	(P = 0.000	02); I² = 74%		
Test for overall effect:	Z = 5.35 (P < 0.00	JUU1)				
MACEs for per % LG						
Omori 2018	0.1044		8.3%	1.11 [0.98, 1.26]		<u>+-</u>
Kwong 2006	0.0862	0.0191		1.09 [1.05, 1.13]	2006	
Subtotal (95% CI)			100.0%	1.09 [1.05, 1.13]		
Heterogeneity: Tau ² = Test for overall effect:			? = 0.78);	I² = 0%		
MACEs for per 10% L	GE					
Yoon 2012		0.1286	68.9%	1.84 [1.43, 2.37]	2012	
Kwong 2008		0.1280	31.1%	1.63 [1.12, 2.37]		_ _
Subtotal (95% CI)	0.4000	0.1010	100.0%	1.77 [1.44, 2.18]	2000	◆
Heterogeneity: Tau ² =	0.00; Chi ² = 0.28,	df = 1 (F	e = 0.60);	I² = 0%		
Test for overall effect:	Z = 5.36 (P < 0.00	001)				

Figure 4. Forest plot of estimates for risks of primary outcomes associated with UMI-CMR. CIs=confidence intervals; UMI-CMR=unrecognized myocardial infarction detected by cardiac magnetic resonance imaging; LGE=late gadolinium enhancement




Figure 5. Heterogeneity of all-cause mortality and cardiac outcomes between UMI and RMI, compared with no MI. (A) UMI detected by ECG; (B) UMI detected by CMR

CMR=cardiac magnetic resonance; MACEs=major adverse cardiovascular events; MI=myocardial infarction; UMI=unrecognized myocardial infarction; RMI=clinical recognized myocardial infarction

1003x1409mm (96 x 96 DPI)

Supplementary file 1. Literature search strategy for Pubmed

- #1 (("myocardial infarction"[Mesh]) OR "myocardial ischemia"[Mesh])
- #2 (("myocardial infarction"[Text Word]) OR "myocardial ischemia"[Text Word])
- **#3 #1** OR **#2**
- #4 (((("unrecognized"[Text Word]) OR "silent"[Text Word]) OR " undiagnosed"[Text Word]) OR
 "asymptomatic"[Text Word])
- **#5 #3** AND **#4**
- #6 animals[MeSH Terms]
- #7 humans[MeSH Terms]
- **#8** #6 NOT #7
- #9 risk [Mesh]
- #10 (((risk[Text Word])OR "hazard ratio"[Text Word]) OR "prognosis" [Text Word])
- **#11** #9 OR #10
- **#12** #8 AND #11

RELERONL

BMJ

Supplementary file 2. Quality assessment of the included studies
--

Study	Selection	Comparability	Outcome	Quality (total
	(points awarded)	(points awarded)	(points awarded)	points)*
UMI detected by EC	G			
Ahmad 2019	3	2	2	Good (7)
Qureshi 2018	3	2	3	Good (8)
Ohrn 2018	3	2	2	Good (7)
Farag 2017	2	1	2	Fair (5)
van der Ende 2017	4	1	2	Good (7)
Zhang 2016	4	2	2	Good (8)
Jovanova 2016	4	2	2	Good (8)
Hadaegh 2015	4	2	3	Good (9)
Dehghan 2014	4	2	2	Good (8)
Davis 2013	3	2	2	Good (7)
Krijthe 2013	4	2	2	Good (8)
Schelbert 2012	4	1	2	Good (7)
Rizk 2012	2	2	3	Good (7)
Kehl 2011	2	1	2	Fair (5)
Leening 2010	4	2	2	Good (8)
Ikram 2006	4	2	2	Good (8)
Ammar 2007	4	1	2	Good (7)
Davis 2004	3	2	2	Good (7)
Menotti 2001	4	2	2	Good (8)
Lampe 2000	4	1	2	Good (7)
UMI detected by CM	IR			
Elliott 2019	3	2	3	Good (8)
Acharya 2018	4	2	2	Good (8)
Nordenskjold 2018	3	1	3	Good (7)
Amier 2018	3	2	2	Good (7)
Omori 2018	3	2	2	Good (7)
Barbier 2016	3	2	3	Good (8)
Yoon 2012	3	2	2	Good (7)
Kim 2009	3	1	3	Good (7)
Kwong 2008	3	2	2	Good (7)
Kwong 2006	3	2	3	Good (8)

* Included studies were graded in quality as good if awarded with \geq 7 points or fair if 4-6 points.

CMR=cardiac magnetic resonance; ECG=electrocardiogram; UMI=Unrecognized myocardial

infarction

Study	Country	Patients characteristics	Sample (% Male)	Age (years) (mean/ range)	ECG diagnositic criteria for UMI	Prevalence of UMI %)	Proportion of UMI in all MI (%)	Follow-up duration (years)	Events for analysis
Ahmad 2019	USA	Community	6323	58.4	A major Q wave abnormality (MC	1.5	NA	14	All-cause death;
		population	(46.1)		1.1 or 1.2) or minor Q/QS wave				CVD mortality
					(MC 1.3) plus major ST-T				
					abnormality (MC 4.1, 4.2, 5.1, or				
					5.2)				
Qureshi 2018	USA	Community	9243	53.7	A major Q wave abnormality (MC	3.4	48	13	Heart failure
		population	(42.8)		1.1 or 1.2) or minor Q/QS wave				
					(MC 1.3) plus major ST-T				
					abnormality (MC 4.1, 4.2, 5.1, or				
					5.2)				
Ohrn 2018	Norway	Community	5686	63	Third universal definition of MI to	7.9	NA	5.5	All-cause death;
		population	(41)		identify prior MI on the ECG *				MI; Stroke
Farag 2017	USA	Chronic kidney	1007	48	Third Universal Definition of	10.7	61.7	2.3	MACEs (all-cause
		disease	(58)		Myocardial Infarction				death, MI, coronary revascularization)
van der Ende	Netherlands	Community	152,124	NA	Third Universal Definition of	0.3	22.9	4	All-cause death
2017		population	(NA)	·	Myocardial Infarction	-			
Jovanova	Netherlands	Community	4237	68.3	Pathologic Q waves and on	5.4	44.5	13.5	All-cause death
2016		population	(45.2)		auxiliary criteria (QR ratio and				
					R-wave progression)				

Supplementary file 3 Characteristics of studies with unrecognized myocardial infarction determined by electrocardiogram

BMJ

Zhang 2016	USA	Community	9498	54.0	A major Q wave abnormality (MC	3.3	45	13.2	All-cause death
-		population	(43.1)		1.1 or 1.2) or minor Q/QS wave				CHD mortality
					(MC 1.3) plus major ST-T				
					abnormality (MC 4.1, 4.2, 5.1, or				
					5.2)				
Hadaegh 2015	Iran	Community	1809	59.7	A major Q wave abnormality (MC	14.9	NA	12.1	All-cause death;
		population	(47.1)		1.1 or 1.2) or complete left bundle				MACEs (all-cause
					branch				death, CHD events,
					block (MC 7.1.1) or minor Q/QS				stroke); CHD
					wave (MC 1.3) plus major ST-T				
					abnormality (MC 4.1, 4.2, 5.1, or				
					5.2)				
Dehghan 2014	Netherlands	Community	6534	69	Pathologic Q waves and on	5.7	45.8	15.6	CVD Mortality
		population	(40.9)		auxiliary criteria (QR ratio and				
					R-wave progression)				
Davis 2013	UK	Type 2 diabetes	1967	52.5	A major Q wave abnormality (MC	16.6	NA	17	All-cause death;
			(59.8)		1.1 or 1.2)				Fatal MI; Non-fatal
						<u>0</u>			MI
Krijthe 2013	Netherlands	Community	6175	68.6	Pathologic Q waves and on	5.4	47.6	11.7	Atrial fibrillation
		population	(40.6)		auxiliary criteria (QR ratio and				
0.1.11	T 1 1		026 (40)	74	R-wave progression)	-	22.2		
Schelbert	Iceland	Community	936 (48)	76	A major Q wave abnormality (MC	5	33.3	6.4	All-cause death
2012 Di-1-2012	USA	population	100/4	(10	1.1 or 1.2)	4.5	20.4		A 11
Rizk 2012	USA	Chronic kidney	18864	64.0	A major Q wave abnormality (MC $1.1 \text{ cm} 1.2$) and $1.0 \text{ cm} 1.2$	4.5	38.4	4	All-cause death
		disease	(37.7)		1.1 or 1.2) or minor Q/QS wave (MC 1.3) plus major ST-T				

					abnormality (MC 4.1, 4.2, 5.1, or 5.2)				
Kehl 2011	USA	Stable coronary artery disease but no history of MI	462 (79.4)	67	A major Q wave abnormality (MC 1.1 or 1.2)	36	NA	6.3	MACEs (all-cause death, nonfatal M and stroke); Nonfatal MI
Leening 2010	Netherlands	Community population	6305 (40.9)	68.7	Pathologic Q waves and on auxiliary criteria (QR ratio and R-wave progression)	3.9	35.9	13.2	Heart failure
Ikram 2006	Netherlands	Community population	6439 (40.4)	68.7	Pathologic Q waves and on auxiliary criteria (QR ratio and R-wave progression)	5.6	45	8.2	Stroke
Ammar 2007	Netherlands	Community population	2029 (48.1)	62.7	A major Q wave abnormality (MC 1.1 or 1.2) or minor Q/QS wave (MC 1.3) plus major ST-T abnormality (MC 4.1, 4.2, 5.1, 5.2, 5.3)	4.0	44.5	5.5	All-cause death
Davis 2004	Australia	Type 2 diabetes	1269 (49.2)	64.1	A major Q wave abnormality (MC 1.1 or 1.2)	3.9	44	7.0	All-cause death CHD mortality
Menotti 2001	Finland Netherlands Italy	Community population	1785 (100)	65-84	A major Q wave abnormality (MC 1.1) or MC $(1.2 + 5.1 \text{ or } 5.2)$	5.9	NA	10	CHD mortality
Lampe 2000	British	Community population	7715 (100)	40-59	A major Q wave abnormality (MC 1.1 or 1.2)	1.7	31.6	10	All-cause death; CHD, Stroke; CVD mortality

RMI=recognized myocardial infarction; UMI=unrecognized myocardial infarction

* Third universal definition of MI to identify prior MI on the ECG as: i) any Q wave in leads $V2-V3 \ge 0.02$ s or QS complex in leads V2 and V3; ii) Q wave ≥ 0.03 s or QS

BMJ

guous lead grouping (1, a . .., complex in any two leads of a contiguous lead grouping (I, aVL; V1–V6; II, III, aVF); or iii) R wave ≥ 0.04 s in V1–V2 and R/S ≥ 1 with a concordant positive T wave in

absence of conduction defect.

BMJ

UMI detected by ECG Ahmad 2019 Age, sex, race, total annual income, smoking, physical activity, SBP, DBP, Yes antihypertensive medications, diuretics, diabetes, BMI, hyperlipidemia, alcohol intake, history of gout, and eGFR. Qureshi 2018 Age, sex, race, BMI, smoking, heart rate, SBP, antihypertensive Yes medications, and diabetes. Ohrn 2018 Age, sex, hypertension, diabetes, smoking, TC, HDL-C, cholesterol Yes lowering medication and family history of premature MI. Farag 2017 Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and No medication intake assumption van der Ende Age, sex, hypertension, diabetes and heart rate No 2017 Jovanova 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, diabetes, RMI No Rizk 2012 Age, sex, diabetes, RMI No Rizk 2012 Age, sex, diabetes, RMI No Rizk 2012 Age, sex, SBP, DBP, smoking, heart failure. Yes cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, SBP, DBP, use of antihyperte	tudy	Confounder adjusted	Adequate
Ahmad 2019 Age, sex, race, total annual income, smoking, physical activity, SBP, DBP, Yes antihypertensive medications, diuretics, diabetes, BMI, hyperlipidemia, alcohol intake, history of gout, and eGFR. Qureshi 2018 Age, sex, race, BMI, smoking, hart rate, SBP, antihypertensive medications, and diabetes. Ohm 2018 Age, sex, hypertension, diabetes, smoking, TC, HDL-C, cholesterol lowering medication and family history of premature MI. Farag 2017 Age, sex, nace, diabetes, hypertension, dyslipidemia, dialysis, and medication intake assumption van der Ende Age, sex, hypertension, diabetes and heart rate No 2017 Jovanova 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Hadaegh 2015 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Yes cognitive impairment, marital, SBP, TC/HDL-C ratio Yes cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes. Schelbert 2012 Age, sex, GBP, DBP, smoking, antihypertensive medication, left ventricula ejection fraction, wall motion score, inducible ischemia No Rizk 2012 Age, sex, SBP, DBP, smoking, C, HDL-C, atrial fibrillation, diabetes, Yes antik-earm pressure index, cardiovacular drugs No Buil, diabetes. COPD, and heart failure, diastolic dysfunction			adjustment†
antihypertensive medications, diuretics, diabetes, BMI, hyperlipidemia, alcohol intake, history of gout, and eGFR. Age, sex, race, BMI, smoking, heart rate, SBP, antihypertensive medications, and diabetes. Ohrn 2018 Age, sex, nace, diabetes, smoking, TC, HDL-C, cholesterol Yes lowering medication and family history of premature MI. Farag 2017 Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and medication intake assumption van der Ende Age, sex, hypertension, diabetes and heart rate No 2017 Jovanova 2016 Age, sex, level of education, smoking, alcohol consumption, history of No stroke, diabetes and SBP. Zhang 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smoking Dehghan 2014 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, chuicty, smoking, HbA1e, SBP, TC/HDL-C ratio Yes Krijthe 2013 Age, sex, diabetes, RMI No Rizk 2012 Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, SBP, DBP, smoking, HaA1e, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2010 Age, sex, SBP, DBP, smoking, heart failure, lacening 2010 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle-arm pressure index, cardiovascular drugs Ammar 2007 Age, sex, diabetes, hypertension, smoking Age, sex, diabetes, hypertension, smoking Age, sex, diabetes, hypertension, smoking Age, sex, diabetes, hypertension, smoking Ammar 2007 Age, sex, diabetes, hypertension, smoking Ammar 2007 Age, sex, diabetes, hypertension, smoking Ammar 2007 Age, sex, diabetes, hypertension, smoking	MI detected by	ECG	
Qureshi 2018 Age, sex, race, BMI, smoking, heart rate, SBP, antihypertensive Yes Mom 2018 Age, sex, hypertension, diabetes, smoking, TC, HDL-C, cholesterol Yes Iowering medication and family history of premature MI. Farag 2017 Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and No wedication intake assumption wedication intake assumption No 2017 Jovanova 2016 Age, sex, hypertension, diabetes and heart rate No Jovanova 2016 Age, sex, level of education, smoking, alcohol consumption, history of No stroke, diabetes and SBP. Zhang 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, diabetes. COPD, and heart failure. Schelbert 2012 Age, sex, region, education, income, smoking, insurance, health care, Yes cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, Yes TC, HDL-C Ikra		antihypertensive medications, diuretics, diabetes, BMI, hyperlipidemia,	Yes
medications, and diabetes. Ohrn 2018 Age, sex, hypertension, diabetes, smoking, TC, HDL-C, cholesterol Ves lowering medication and family history of premature MI. Farag 2017 Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and medication intake assumption No van der Ende Age, sex, hypertension, diabetes and heart rate No 2017 Jovanova 2016 Age, sex, level of education, smoking, alcohol consumption, history of No stroke, diabetes and SBP. Zhang 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, sBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, diabetes. COPD, and heart failure. Schelbert 2012 Age, sex, diabetes, RMI No Rizk 2012 Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemia No Leening 2010 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, Masmoking, Yes ankle-arm pressure index, cardiovascular drugs Yes ankle-arm pressure index, cardiovascular drugs Mentry Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankl			Yes
Iowering medication and family history of premature MI.Farag 2017Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and medication intake assumptionvan der Ende 2017Age, sex, hypertension, diabetes and heart rateNoJovanova 2016Age, sex, level of education, smoking, alcohol consumption, history of stroke, diabetes and SBP.NoZhang 2016Age, sex, race, study center, BMI, income, education, smoking, SBP, antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinineHadaegh 2015Hadaegh 2015Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, and type 2 diabetes.Yes BMI, and type 2 diabetes.Davis 2013Age, sex, stBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, diabetes. COPD, and heart failure.NoSchelbert 2012Age, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesNoKehl 2011Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, ventricular ejection fraction, wall motion score, inducible ischemia Leening 2010Age, sex, sthe of antihypertensive drugs, BMI, DM, smoking, Yes ankle-arm pressure index, cardiovascular drugsYes ankle-arm pressure index, cardiovascular drugsAmmar 2007Age, sex, diabetes, hypertension, smoking Davis 2004Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseNo	-		100
Farag 2017 Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and medication intake assumption No van der Ende Age, sex, hypertension, diabetes and heart rate No 2017 Jovanova 2016 Age, sex, level of education, smoking, alcohol consumption, history of stroke, diabetes and SBP. No Zhang 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Hadaegh 2015 Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smoking Dehghan 2014 Dehghan 2014 Age, sex, sBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Yes Davis 2013 Age, sex, ethnicity, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, diabetes. COPD, and heart failure. No Schelbert 2012 Age, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes No Kehl 2011 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, Yes TC, HDL-C Yes ankle-arm pressure index, cardiovascular drugs Ammar 2007 Age, sex, diabetes, hypertension, smoking No Yes ankle-arm pressure index, cardiovascular drugs No			Yes
van der Ende 2017Age, sex, hypertension, diabetes and heart rateNo2017Jovanova 2016Age, sex, level of education, smoking, alcohol consumption, history of stroke, diabetes and SBP.NoZhang 2016Age, sex, race, study center, BMI, income, education, smoking, SBP, antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinineYes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinineHadaegh 2015Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smokingDehghan 2014Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, and type 2 diabetes.Davis 2013Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratioYes BMI, diabetes. COPD, and heart failure.Schelbert 2012Age, sex, diabetes, RMIRizk 2012Age, sex, diabetes, RMIRizk 2012Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemiaLeening 2010Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, ventricular ejection fraction, wall motion score, inducible ischemiaLeening 2007Age, sex, diabetes, hypertension, moking ankle–arm pressure index, cardiovascular drugsAnnmar 2007Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise	arag 2017	Age, sex, race, diabetes, hypertension, dyslipidemia, dialysis, and	No
2017 Jovanova 2016 Age, sex, level of education, smoking, alcohol consumption, history of No stroke, diabetes and SBP. Zhang 2016 Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinine Hadaegh 2015 Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smoking Dehghan 2014 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, sex, GPD, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, diabetes. COPD, and heart failure. Schelbert 2012 Age, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, TC, HDL-C Ikram 2006 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, regunitive impersure index, cardiovascular drugs Ammar 2007 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle-arm pressure index, cardiovascular drugs Ammar 2004 Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive redication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise		-	No
stroke, diabetes and SBP.Zhang 2016Age, sex, race, study center, BMI, income, education, smoking, SBP, Yes antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinineHadaegh 2015Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smokingDehghan 2014Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, and type 2 diabetes.Davis 2013Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratioYes BMI, diabetes. COPD, and heart failure.Schelbert 2012Age, sex, region, education, income, smoking, insurance, health care, 		Age, sex, hypertension, diabetes and heart rate	INO
antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol lowering medications, aspirin, family history of CAD and serum creatinineHadaegh 2015Age, sex, BMI, impaired glucose regulation, hypertension, hypercholesterolemia, and smokingDehghan 2014Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, and type 2 diabetes.Davis 2013Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratioYes Krijthe 2013Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, diabetes. COPD, and heart failure.Schelbert 2012Age, sex, diabetes, RMIRizk 2012Age, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesKehl 2011Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, rC, HDL-CIkram 2006Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, ankle-arm pressure index, cardiovascular drugsAmmar 2007Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise			No
 Hadaegh 2015 Age, sex, BMI, impaired glucose regulation, hypertension, Yes hypercholesterolemia, and smoking Dehghan 2014 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, and type 2 diabetes. Davis 2013 Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratio Yes Krijthe 2013 Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, Yes BMI, diabetes. COPD, and heart failure. Schelbert 2012 Age, sex, diabetes, RMI No Rizk 2012 Age, race, sex, region, education, income, smoking, insurance, health care, Yes cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, Yes TC, HDL-C Ikram 2006 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle–arm pressure index, cardiovascular drugs Ammar 2007 Age, sex, diabetes, hypertension, smoking Davis 2004 Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive Yes medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise 	;	antihypertensive medications, diabetes, ratio of TC/HDL-C, cholesterol	Yes
Dehghan 2014Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, and type 2 diabetes.Yes BMI, and type 2 diabetes.Davis 2013Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratioYesKrijthe 2013Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, diabetes. COPD, and heart failure.YesSchelbert 2012Age, sex, diabetes, RMINoRizk 2012Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesNoKehl 2011Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemiaNoLeening 2010Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, TC, HDL-CYes ankle–arm pressure index, cardiovascular drugsAmmar 2007Age, sex, diabetes, hypertension, smoking Davis 2004NoAge, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseYes	ladaegh 2015	Age, sex, BMI, impaired glucose regulation, hypertension,	Yes
Davis 2013Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratioYesKrijthe 2013Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C,YesBMI, diabetes. COPD, and heart failure.Schelbert 2012Age, sex, diabetes, RMINoRizk 2012Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesNoKehl 2011Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemiaNoLeening 2010Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, TC, HDL-CYes ankle-arm pressure index, cardiovascular drugsYes ankle-arm pressure index, cardiovascular drugsAmmar 2007Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseYes	ehghan 2014	Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C,	Yes
Krijthe 2013Age, sex, SBP, DBP, smoking, antihypertensive medication, TC, HDL-C, BMI, diabetes. COPD, and heart failure.Schelbert 2012Age, sex, diabetes, RMINoRizk 2012Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesNoKehl 2011Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemiaNoLeening 2010Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, TC, HDL-CYes ankle–arm pressure index, cardiovascular drugsAmmar 2007Age, sex, diabetes, hypertension, smoking Davis 2004NoYes medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseYes	avis 2013	Age, sex, ethnicity, smoking, HbA1c, SBP, TC/HDL-C ratio	Yes
Schelbert 2012Age, sex, diabetes, RMINoRizk 2012Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetesYesKehl 2011Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemiaNoLeening 2010Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, TC, HDL-CYesIkram 2006Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, ankle–arm pressure index, cardiovascular drugsYesAmmar 2007Age, sex, diabetes, hypertension, smoking medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseYes	-		Yes
 Rizk 2012 Age, race, sex, region, education, income, smoking, insurance, health care, Yes cognitive impairment, marital, SBP, anti-hypertensive medication, dyslipidemia and diabetes Kehl 2011 Age, sex, ethnicity, smoking, heart failure, diastolic dysfunction, left ventricular ejection fraction, wall motion score, inducible ischemia Leening 2010 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, Yes TC, HDL-C Ikram 2006 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle–arm pressure index, cardiovascular drugs Ammar 2007 Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive Yes medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise 			No
 ventricular ejection fraction, wall motion score, inducible ischemia Leening 2010 Age, sex, SBP, DBP, use of antihypertensive drugs, BMI, DM, smoking, Yes TC, HDL-C Ikram 2006 Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle–arm pressure index, cardiovascular drugs Ammar 2007 Age, sex, diabetes, hypertension, smoking No Davis 2004 Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive Yes medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise 	izk 2012	Age, race, sex, region, education, income, smoking, insurance, health care, cognitive impairment, marital, SBP, anti-hypertensive medication,	Yes
TC, HDL-CIkram 2006Age, sex, SBP, DBP, smoking, TC, HDL-C, atrial fibrillation, diabetes, Yes ankle–arm pressure index, cardiovascular drugsAmmar 2007Age, sex, diabetes, hypertension, smokingNoDavis 2004Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseYes			No
ankle–arm pressure index, cardiovascular drugsAmmar 2007Age, sex, diabetes, hypertension, smokingNoDavis 2004Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensiveYesmedication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseNo	•		Yes
Ammar 2007Age, sex, diabetes, hypertension, smokingNoDavis 2004Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensiveYesmedication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exerciseNo			Yes
Davis 2004 Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive Yes medication, lipid-lowering therapy, serum creatinine, microalbuminuria, retinopathy, neuropathy, smoking, exercise			No
	Davis 2004	Age, sex, marital status, education, diabetes, BMI, SBP, antihypertensive medication, lipid-lowering therapy, serum creatinine, microalbuminuria,	Yes
Menotti 2001 Age, BP, smoking, TC, BMI Yes		Age, BP, smoking, TC, BMI	Yes

Supplementary file 4. Confounders Adjusted of the Included Studies

Page 47 of 57

Lampe 2000	Age	No
UMI detected h	by CMR	
Elliott 2019	LVEF, Framingham risk score, diabetes type	Yes
Acharya 2018	Age, sex, diabetes, smoking, hypertension, TC, HDL-C, statin use, BMI, eGFR.	Yes
Nordenskjold	Age, sex, hypertension, NT-proBNP, extent of CAD	No
2018		
Amier 2018	Age, sex, study site, pre-hospital medication, type of acute MI, number of	No
	vessel disease, reperfusion strategy, LVEF, total infarct size and	
	microvascular obstruction.	
Omori 2018	Age, sex, hypertension, diabetes dyslipidaemia, smoking, obesity, history	Yes
	of CAD, Killip classification medications, laboratory results, angiographic	
	findings, CMR findings	
Barbier 2016	Sex, Framingham Risk Score	Yes
Yoon 2012	Age, sex, hypertension, hypercholesterolemia, smoking, family history of	Yes
	CAD, BMI, history of CAD, revascularization, LVEF, LV wall motion	
	abnormalities	
Kim 2009	Candidate variables with p<0.10 from the univariable analysis (NYHA	No
	class, LVEF, non-Q-wave UMI, and revascularization during the	
	follow-up period)	
Kwong 2008	Age, sex, ST or T changes on ECG, and end-systolic volume index, 5-year	Yes
-	probability of a cardiac event by the UKPDS risk model	
Kwong 2006	Age, sex, race, BMI, heart rate, smoking, diabetes, hypertension,	Yes
-	hypercholesterolemia, PCI, CABG, status of coronary stenosis on	
	angiography, noninvasive assessment of myocardial ischemia, CMR	
	predictors	


[†]Adequate adjustment denoted adjustment of at least six of seven factors: sex; age; hypertension or blood pressure or antihypertensive treatment; diabetes mellitus or fasting plasma glucose or hemoglobin A1c; body mass index or overweight/obesity; cholesterol or hypercholesterolemia and smoking or adjusted for risk score calculated from these metrics

BMI=body mass index; CABG=Coronary Artery Bypass Grafting; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; CMR=cardiac magnetic resonance; DBP=diastolic blood pressure; ECG=electrocardiography; eGFR=estimated glomerular filtration rate; HDL-C= high-density lipoprotein cholesterol; MC=Minnesota code; MI=myocardial infarction; PCI=percutaneous coronary intervention; RMI=recognized myocardial infarction; SBP=systolic blood

<text>

BMJ

59 60



s coronary neuri alsease, inneeds major adverse cardiovascular events, inn myo

infarction; UMI=unrecognized myocardial infarction

Study	Country	Patients	Sample size	Age (years)	Prevalence	Proportion	Follow-u	Events for analysis
		characteristics	(% Male)	(mean/range)	of UMI in the cohort	of UMI in all MI (%)	p duration	
					(%)		(years)	
Elliott 2019	USA	Diabetes	120 (54)	52	19	NA	5	MACEs (All-cause death or MI)
Acharya 2018	Iceland	Community population	935 (48.3)	76	17	63.2	10.5	All-cause death; MACEs (all-cause death, nonfatal MI, and heart failure); New MI; Heart failure
Nordenskjold 2018	Sweden	Suspected stable CAD	235 (66)	65	25	NA	5.4	MACEs (cardiovascular mortality, resuscitated cardiac arrest, MI, hospitalization for angina pectoris, heart failure)
Amier 2018	Netherlands	Acute MI	392 (77)	58.3	8.2	NA	6.8	All-cause death; MACEs (all-cause death, reinfarction, coronary artery bypass grafting, and ischemic stroke)
Omori 2018	Japan	Acute MI	269 (78)	66	13	NA	1.8	MACEs (cardiovascular mortality, non-fatal MI, unstable angina requiring revascularization, fatal arrhythmia, and heart failure)
Barbier 2016	Sweden	Community population	248 (50.4)	71	22.2	83.3	11	MACEs (cardiovascular mortality, non-fatal MI, a new diagnosis of angina pectoris, or coronary artery revascularization)
Yoon 2012	Japan	Impaired Fasting	332 (67.2)	68	31	NA	2.5	MACEs (cardiovascular mortality, new

Supplementary file 6. Characteristics of studies with unrecognized myocardial infarction determined by cardiac magnetic resonance

https://mc.manuscriptcentral.com/bmj


Page 51 of 57

1	
2 3	
3 4	
5 6	
7	
8 9	
10	
11 12	
13 14	
15	
16 17	
12 13 14 15 16 17 18 19 20	
19 20	
20 21 22 23 24 25	
22 23	
24 25	
26	
27 28	
29	
30 31	
32	
33 34	
35 36	
30 37	
38 39	
40	
41 42	
43	
44 45	
15	

46

		Glucose or						acute MI, unstable angina necessitating
		Diabetes						hospitalization, heart failure of
								ventricular arrhythmias necessitating an
								internal cardioverter and/o
								defibrillator)
Kim 2009	USA	Suspected stable	185 (66)	60.4	27	NA	2.2	All-cause death; Cardiovascula
		CAD						mortality,
Kwong 2008	USA	Diabetes	107 (63)	59 (13)	28	51.0	1.4	MACEs (all-cause death, new acute
								MI, unstable angina requiring
								hospitalization, heart failure;
								ventricular arrhythmias requiring
								internal cardioverter and/or
								defibrillator, and acute cerebral
								vascular accidents)
Kwong 2006	USA	Suspected stable	195 (68)	59 (13)	22.7	NA	1.3	MACEs (cardiac death, new acute MI,
		CAD						unstable angina requiring
								hospitalization, heart failure requiring
								hospitalization, or ventricular
								arrhythmias requiring internal
								cardioverter and/or defibrillator;
								Cardiovascular mortality,

CAD=coronary artery disease; MACEs=major adverse composite cardiovascular events; MI= myocardial infarction; UMI=unrecognized myocardial infarction





SE(log[RR]) 0 0.5 0 1.5 RR 0.02 0.1 10 50 Subgroups O All cause mortality Cardiovascular mortality MACEs

Supplementary file 7. Funnel plot of primary outcomes between UMI detected by

CMR and non-MI

CMR=cardiac magnetic resonance; MACEs=major adverse cardiovascular events; MI=myocardial periez oni

infarction; UMI=unrecognized myocardial infarction

All-cause mortality	No of stud	lies			HR (95% CI)	P value
RMI vs UMI-ECG	5			• •	1.31 (0.81-2.81)	0.27
RMI vs UMI-CMR	1	H	•		0.92 (0.62-1.37)	0.68
Cardiovascular morta	lity					
RMI vs UMI-ECG	3			•	1.74 (0.91-3.31)	0.09
RMI vs UMI-CMR	NA					
MACEs						
RMI vs UMI-ECG	1		•		1.06 (0.64-1.74)	0.82
RMI vs UMI-CMR	2		•		1.13 (0.57-2.23)	0.73
Recurrent CHD/ MI						
RMI vs UMI-ECG	1			• •		0.002
RMI vs UMI-CMR	1		- <u>-</u>	• 1	1.55 (0.87-2.75)	0.14
Stroke						
RMI vs UMI-ECG	1		•		1.09 (0.50-2.39)	0.83
RMI vs UMI-CMR	NA					
Heart failure						
RMI vs UMI-ECG	2		-		1.84 (1.42-2.38)	<0.00
RMI vs UMI-CMR	1		+	•	1.56 (0.93-2.61)	0.09
0.25	0	.5	1	2	4	

Supplementary File 8. The relative risks of all-cause mortality and cardiac

outcomes in patients with RMI compared with those with UMI

MACEs=major adverse cardiovascular events; MI=myocardial infarction; RMI=recognized MI;

UMI-CMR=unrecognized MI detected by cardiac magnetic resonance; UMI-ECG=unrecognized MI

detected by electrocardiogram

BMJ

Supplementary file 9. Subgroup	analyses of the association between UM	I-ECG and risk of primary outcomes
--------------------------------	--	------------------------------------

		All-cause mortali	ty	Cardiovascular mortality				MACEs			
	Number of	HR (95%CI)	P value* /	Number of	HR (95%CI)	P value* /	Number	of	HR (95%CI)	P value* /	
	Studies	- MA	$I^{2}(\%)$	Studies		$I^{2}(\%)$	Studies			I ² (%)	
Age											
<65 years	8	1.40 [1.26, 1.56]	0.86/0	5	2.28 [1.50, 3.46]	0.81/0	1		1.43 [0.96, 2.13]	0.77/0	
≥65 years	4	1.42 [1.25, 1.61]		2	2.54 [1.13, 5.69]		2		1.65 [1.39, 1.97]		
Sex											
Male	3	1.45 [1.23, 1.70]	0.59/0	3	3.74 [2.70, 5.18]	0.98/0	2		1.76 [1.41, 2.20]	0.63/0	
Female	3	1.36 [1.17, 1.59]		1	3.79 [1.65, 8.71]		2		1.47 [1.07, 2.02]		
Ethnicity											
Asian	1	1.56 [1.04, 2.34]	0.73/0	-	- 0	NA	1		1.68 [1.37, 2.06]	0.77/0	
Non-Asian	10	1.40 [1.26, 1.54]		7	2.33 [1.66, 3.27]		2		1.52 [1.17, 1.96]		
Enrollment from	n community-l	oased population									
Yes	8	1.59 [1.32, 1.91]	0.17/47.1	5	2.67 [1.77, 4.02]	0.04/77.5	1		1.68 [1.37, 2.06]	0.77/0	
No	3	1.34 [1.15, 1.56]		2	1.59 [1.24, 2.04]		2		1.52 [1.17, 1.96]		
All participants	with diabetes										
Yes	3	1.30 [1.11, 1.54]	0.12/59.7	2	1.58 [1.22, 2.05]	0.03/77.7	1		1.11 [0.73, 1.68]	0.10/63.4	
No	10	1.59 [1.33, 1.90]		5	2.67 [1.77, 4.02]		2		1.62 [1.35, 1.95]		
Follow-up dura	tion										
<6 years	4	1.62 [1.27, 2.06]	0.55/0	-	-	NA	1		1.58 [1.13, 2.21]	0.77/0	
≥6 years	7	1.48 [1.24, 1.77]		7	2.33 [1.66, 3.27]		2		1.62 [1.35, 1.95]		
Adjustment of c	onfounders										
Adequate [†]	7	1.41 [1.29, 1.53]	0.30/8.1	5	2.16 [1.51, 3.08]	0.02/81.2	1		1.68 [1.37, 2.06]	0.77/0	
Inadequate	4	1.85 [1.11, 3.09]		1	4.40 [2.70, 7.17]		2		1.52 [1.17, 1.96]		

 * For heterogeneity among subgroups. †Adequate adjustment denoted adjustment of at least six of seven factors: sex; age; hypertension or blood pressure or antihypertensive

BMJ

Lectrocardiography; MACEs: major adverse cardiovascular. treatment; diabetes mellitus or fasting plasma glucose or hemoglobin A1c; body mass index or overweight/obesity; cholesterol or hypercholesterolemia and smoking or

adjusted for risk score calculated from these metrics

UMI-ECG: unrecognized myocardial infarction detected by electrocardiography; MACEs: major adverse cardiovascular events; NA: Not applicable

Supplementary file 1	0. Subgroup analyses	of the association between	n UMI-CMR and risk of	primary outcomes
Suppremental y me i		of the association set (cer		Ji mai j ou comes

	All-cause mortality			(Cardiovascular mortali					
	Number of	HR (95%CI)	P value* /	Number of	HR (95%CI)	P value* /	Number	of HR	HR (95%CI)	P value* /
	Studies		I ² (%)	Studies		I ² (%)	Studies			I ² (%)
Age										
<65 years	3	4.52 [2.29, 8.90]	0.005/87.5	2	10.79 [4.09, 28.42]	NA	4	4.7	6 [3.13, 7.22]	0.02/80.7
≥65 years	1	1.60 [1.26, 2.03]		-	-		5	2.3	7 [1.54, 3.65]	
Ethnicity										
Asian	-	-	NA	151	-	NA	2	3.6	8 [2.12, 6.39]	0.68/0
Non-Asian	4	3.21 [1.43, 7.23]		2	10.79 [4.09, 28.42]		7	3.1	5 [1.90, 5.23]	
Enrollment from	n community-	based population								
Yes	1	1.60 [1.26, 2.03]	0.005/87.5	-		NA	2	1.7	2 [1.08, 2.74]	0.005/87.4
No	3	4.52 [2.29, 8.90]		2	10.79 [4.09, 28.42]		7	3.8	0 [2.82, 5.12]	
All participants	with diabetes									
Yes	1	3.38 [1.24, 9.21]	0.99/0	-	- 16	NA	3	4.4	3 [2.71, 7.23]	0.13/55.9
No	3	3.41 [1.11, 10.48]		2	10.79 [4.09, 28.42]		6	2.6	4 [1.66, 4.20]	
Follow-up dura	tion									
<6 years	2	4.89 [2.12, 11.29]	0.01/83.2	2	10.79 [4.09, 28.42]	NA	3	3.9	3 [2.80, 5.52]	0.02/82.2
≥ 6 years	2	1.66 [1.31, 2.10]		-	-		6	1.9	5 [1.21, 3.12]	
Adjustment of c	confounders									
Adequate [†]	2	1.97 [1.02, 3.81]	0.08/67.7	1	9.43 [3.15, 28.23]	0.61/0	7	3.4	7 [2.02, 5.98]	0.42/0
Inadequate	2	5.92 [2.10, 16.67]		1	17.40 [2.20, 137.61]		2	2.5	4 [1.49, 4.32]	

* For heterogeneity among subgroups. †Adequate adjustment denoted adjustment of at least six of seven factors: sex; age; hypertension or blood pressure or antihypertensive

treatment; diabetes mellitus or fasting plasma glucose or hemoglobin A1c; body mass index or overweight/obesity; cholesterol or hypercholesterolemia and smoking or

BMJ

adjusted for risk score calculated from these metrics

UMI-CMR=unrecognized myocardial marcun... No data available for subgroup analysis for sex. UMI-CMR=unrecognized myocardial infarction detected by cardiac magnetic resonance; MACEs= major adverse cardiovascular events; NA=Not applicable